NEWARK, New Jersey, October 6, 2021 / PRNewswire / – Rafael Holdings, Inc., (NYSE: RFL), a pharmaceutical holding company focused on developing novel therapies for cancer metabolism through its Barer Institute and investment in Rafael Pharmaceuticals, Inc., today announced the appointment of Mary Margaret (Mimi) Huizinga, MD, MPH as head of development and medical director, effective October 18, 2021.
“Dr. Huizinga’s appointment reflects the importance of the Company’s advanced stage clinical programs,” said Ameet Mallik, CEO of Rafael Holdings, Inc. “His development and regulatory experience within the pharmaceutical industry, along with his deep oncology expertise and proven track record make him an ideal addition to our leadership team as we continue to develop therapies against cancer metabolism. “
Dr Huizinga most recently served as the US Head of Medical Oncology for Novartis, overseeing the clinical development and medical affairs activities of Novartis’ oncology portfolio in the US. Prior to leading the medical function, Dr. Huizinga built and led the strategic data and digital function in the oncology business unit in the United States at Novartis. The strategic data and digital function included real-world evidence, health economics, and clinical evidence and value linkages, in addition to supporting digital marketing and building a data strategy and platform. During his time at Novartis, Dr. Huizinga has been involved in more than a dozen product and indication launches. Prior to Novartis, she was the Director of Health Information at Premier, Inc, where she also led the Applied Sciences division in partnership with several pharmaceutical companies around the needs of evidence generation. Dr Huizinga was previously Vice President of Quality at Lifepoint Health, Partner at McKinsey & Company and Associate Professor at Johns Hopkins University. Dr Huizinga holds a doctorate in medicine and an MPH from Vanderbilt University and is a fellow of the American College of Physicians.
“It’s exciting to join the Rafael Holdings management team later this month. I look forward to working with the Rafael Pharmaceuticals organization in the development of cancer metabolism therapy programs as they approach a critical inflection point with reading data for their Phase 3 clinical trial for the CPI- 613® in metastatic pancreatic cancer in the fourth trimester of this year, ”said Dr. Huizinga.
About Rafael Holdings, Inc.
Rafael Holdings is focused on the development of new cancer therapies. The company owns the Barer Institute and is a significant investor in two clinical stage oncology companies, Rafael Pharmaceuticals, Inc. and LipoMedix Pharmaceuticals Ltd. Through the Barer Institute, the company is developing a pipeline of compounds focused on regulating cancer metabolism. On June 21, 2021, Rafael Holdings, Inc. (NYSE: RFL) announced that it had entered into a merger agreement to acquire full ownership of Rafael Pharmaceuticals, Inc. For more information, visit www.rafaelholdings.com.
About Rafael Pharmaceuticals, Inc.
Rafael Pharmaceuticals is a clinical-stage oncology company focused on the selective targeting of cancer metabolic pathways while simultaneously harnessing the immune system to attack hard-to-treat cancers. The Company’s flagship drug, CPI-613® (devimistat), is under evaluation in several clinical studies, including two Phase 3 registration clinical trials for metastatic pancreatic cancer and acute myeloid leukemia r / r. Several phase 1/2 clinical trials are underway or planned in the areas of biliary, Burkitt’s r / r, r / r of clear cell sarcoma, r / r of T cell lymphoma, r / r of MDS and cancer colorectal.
The Company plans to continue to discover and advance its internal cancer metabolism research programs and expects its Dual-SHMT inhibitor to enter phase 1 in late 2022 / early 2023. The Company’s investors include Rafael Holdings, Inc. (NYSE: RFL). For more information, please visit www.rafaelpharma.com.
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements contained in this press release that do not relate to historical facts should be considered as forward-looking statements, including, but without limitation, statements regarding our expectations regarding the potential, safety, efficacy and regulatory and clinical progress of our product candidates; plans and schedule for publication of additional clinical data; and the potential of our pipeline, including our internal cancer metabolism research programs. These statements are not promises or guarantees, but involve known and unknown risks, uncertainties and other important factors that may cause our actual results, performance or achievements to be materially different from future results, performance or achievements. expressed or implied by forward-looking statements. statements, including, but not limited to the following: the impact of public health threats, including COVID-19, on our business and operations; we are highly dependent on the success of Rafael Pharmaceuticals and the future success of its lead product candidate, devimistat (CPI-613® (devimistat)), and clinical trials of the product candidate may not be successful; our pharmaceutical companies may not be able to develop drugs with commercial value; our pharmaceutical companies may not be successful in their efforts to identify or discover potential product candidates; the manufacture and development of the manufacture of our products and product candidates present technological, logistical and regulatory risks, each of which could have a negative impact on our potential revenues; potential unforeseen events during clinical trials could cause delays or other undesirable consequences; risks associated with the regulatory approval process; interim, initial and preliminary data may change as more patient data becomes available, and is subject to audit and verification procedures which could result in significant changes in the final data; our product candidates may cause serious unwanted side effects; ongoing regulatory obligations; effects of significant competition; unfavorable tariff regulations, third party reimbursement practices or healthcare reform initiatives; product liability lawsuits; the inability to attract, retain and motivate qualified personnel; the possibility of system failures or security breaches; intellectual property risks and significant costs resulting from operating as a public enterprise. These and other important factors discussed under the heading “Risk Factors” in our Annual Report on Form 10-K for the year ended July 31, 2020, and our other documents filed with the SEC could cause actual results to differ materially from those indicated by forward-looking statements made in this press release. These forward-looking statements represent management’s estimates as of the date of this press release. While we may choose to update these forward-looking statements at some time in the future, we disclaim any obligation to do so, even if subsequent events change our view.
Show original content:
SOURCE Rafael Holdings, Inc.